<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60481">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025335</url>
  </required_header>
  <id_info>
    <org_study_id>2013-1040</org_study_id>
    <secondary_id>2013-1040</secondary_id>
    <nct_id>NCT02025335</nct_id>
  </id_info>
  <brief_title>Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients</brief_title>
  <acronym>ACE-KT</acronym>
  <official_title>Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients (ACE-KT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CMV is one of the most important opportunistic infection in transplant recipients. In South
      Korea, more than 95% of adults reveal sero-positivity for CMV IgG. Until now,
      sero-positivity for CMV IgG before solid organ transplantation is a laboratory test of
      choice to stratify the risk of CMV reactivation after solid organ transplantation.
      Theoretically, CMV-specific cell-mediate immune response before solid organ transplantation
      will further categorize the patients into high or low risk of CMV development after solid
      organ transplantation. The investigators thus evaluate the usefulness of CMV-specific
      ELISPOT assay in kidney transplant candidates to predict the development of CMV infection
      after kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between Feb 2014 and July 2014, all patients admitted in the kidney transplant unit will be
      enrolled in this study. All patients will receive CMV-specific ELISPOT assay and be
      prospectively followed for the development of CMV infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>CMV infection</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV infection is defined as follows.
CMV viremia: CMV antigenemia or CMV quantitative PCR (+)
CMV disease: CMV syndrome or tissue-invasive CMV disease i) CMV syndrome: ① CMV viremia ② temperature &gt; 38 without other cause ③ WBC &lt; 4000, atypical lymphocyte &gt; 3%, transaminase elevation, platelet &lt; 100,000/mm ii) tissue-invasive CMV disease: evidence of CMV in histopathologic specimen (inclusion body or viral antigen in biopsy or bronchoalveolar lavage fluid)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft loss</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Kidney Transplantation Recipients</condition>
  <arm_group>
    <arm_group_label>high CMV ELISPOT results</arm_group_label>
    <description>high spot counts in ELISPOT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low CMV ELISPOT results</arm_group_label>
    <description>low spot counts in ELISPOT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Kindeny transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 16 or more

          -  agree with written informed consent

          -  WBC count 2000/uL or more

        Exclusion Criteria:

          -  donor CMV IgG (+) and recipient CMV IgG (-)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Han Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Han Kim, MD</last_name>
    <phone>82-2-3010-3305</phone>
    <email>kimsunghanmd@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Han Kim, MD</last_name>
      <phone>82-2-3010-3305</phone>
      <email>kimsunghanmd@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Sung-Han Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
